ACST Acasti Pharma Inc.

1.05
+0.04  (+4%)
Previous Close 1.01
Open 1.01
Price To Book 3.62
Market Cap 82,039,371
Shares 78,132,734
Volume 3,026,555
Short Ratio
Av. Daily Volume 300,076

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due in December 2019 (1) and January 2020 (2).
CaPre (TRILOGY 1 and 2)
Hypertriglyceridemia

Latest News

  1. Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition
  2. Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia
  3. Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer
  4. Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
  5. Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel
  6. Acasti Settles Claims with Former Chief Executive Officer
  7. Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City
  8. Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
  9. Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal
  10. Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd
  11. Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
  12. Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50
  13. Acasti: Fiscal 3Q Earnings Snapshot
  14. Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
  15. Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call
  16. 4 Healthcare Stocks Looking To Set January Highs
  17. Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
  18. Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan
  19. Generic Industry on Path to Recovery: 3 Hot Picks for 2019
  20. Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia